What's New
Forgot Password
New Users
Corporate Info
IPO
News
Other Markets
MF Schemes
MF Trends
MF Buzz
MF Tools
Knowledge
MF Disclosure
Insurance
Reports
Tools
BSE
Quotes
MARKET ANALYSIS
NEWS
CORPORATE INFORMATION
CORPORATE ACTIONS
OTHER MARKETS
Gainers & Losers
Live Indices
Index Movers
Value & Volume Toppers
Advances & Declines
Only Buyers/Sellers
Bulk Deals
Block Deals
Sector Watch
New Highs & Lows
52 Week Highs & Lows
Out/Under Performers
Index Constituents
Unusual Volume
Historical Returns
Exchange Holidays
Pre-Session
Mid-Session
End-Session
Quick Peek
Market Beat
Stock Alert
Corporate Results
Foreign Markets
Economy News
Corporate News
Other Markets
Futures Market
Analyst Poll
Hot Pursuit
Business News
MutualFund News
IPO News
Detailed Quotes
Company Snapshot
Company Background
Board of Directors
Profit & Loss
Quarterly Result
Balance Sheet
Financial Ratios
Share Price
Director's Report
Score Board
MF Holdings
Share Holding Pattern
Name Change
Price Chart
Share Price Analysis
Company News
Peer Comparison
Interactive Chart
BSE Announcements
Board Meetings
Book Closure
Bonus Issues
Rights Issues
Delisted Shares
Market Turnover
Change of Name
Split Of Face Value
ADR Prices
FII Investment
MF Investment
Forex
World Indices
Your Result on :
Company News
Cipla Ltd
Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
500087
ISIN Demat
INE059A01026
Book Value (
R
s
)
432.1356994
NSE Symbol
CIPLA
Divident Yield %
0.92
Market Cap
(
R
s
In Cr.)
114,720
P/E (TTM)
40.17
EPS (TTM)
35.35
Face Value
(
R
s
)
2
Date
Heading
27-Oct-26
Cipla slips after Q2 PAT drops 35% YoY
27-Oct-26
Cipla consolidated net profit declines 35.05% in the September 2026 qu
05-Oct-26
Cipla Ltd under sustained pressure
29-Sep-26
Cipla to announce Quarterly Result
24-Sep-26
Cipla allots 12,168 equity shares under ESOS
18-Sep-26
Cipla receives ESG rating of 68
04-Sep-26
Invagen Pharmaceuticals enters licensing agreement with Qilu
04-Sep-26
Cipla inks exclusive partnership with Qilu Pharma for commercializing
01-Sep-26
Cipla inks exclusive licensing agreement with SBP Group for ADC Roldit
31-Aug-26
Cipla and SBP Group sign exclusive license agreement for Rolditamig De
04-Aug-26
InvaGen receives EIR report for its facility in Hauppauge, New York
23-Jul-26
Cipla consolidated net profit declines 39.19% in the June 2026 quarter
23-Jul-26
Cipla drops after Q1 PAT tumbles 39% YoY to Rs 789 cr
23-Jul-26
Board of Cipla approves change in senior management
23-Jul-26
Cipla grants 24,709 stock options and ESARs
PREV |
NEXT
Risk Factor
|
Terms & Conditions
|
Privacy Policy
|
Disclaimer
|
Sitemap
Important Links:
SEBI
|
NSE
|
BSE
|
MCX
|
NCDEX
|
NSDL
|
CDSL
|
FMC
BSE Delayed market data sourced at 5 minutes –
www.bseindia.com
SMS FINANCIAL SERVICES P. LTD -NSE SEBI No. AP1413004363 | BSE SEBI No. AP01091801121968
Ganesh S Shanbhag – AMFI Registered Mutual Fund Distributor. Registration Number – ARN-0988 – Valid Till 01/JUL/ 2027, Date of initial registration: 02/DEC/2004
2017-18 © SMS Financial Services. All rights reserved.
Designed, Developed , Maintained and Content Powered by
CMOTS InfoTech
(ISO 9001:2015 & ISO/IEC 27001:2022 Certified)